The Development of Diabetic Retinopathy in Goto-Kakizaki Rat and the Expression of Angiogenesis-Related Signals

10.4077/CJP.2016.BAE383

Chen-Yuan Gong；Bin Lu；Yu-Chen Sheng；Zeng-Yang Yu；Jian-Yuan Zhou；Li-Li Ji

angiogenesis ； diabetic retinopathy ； Goto-Kakizaki rat ； MMP2/9 ； PDGFA/B ； VEGF

The Chinese Journal of Physiology

59卷2期（2016 / 04 / 30）

100 - 108

英文

The Goto-Kakizaki (GK) rat is a genetic model of type 2 diabetes. Diabetic retinopathy (DR) is a common complication of diabetes. In this study, we observed the development of DR in GK rats and the expression of some angiogenesis-related signals. GK rats were housed for 5, 6 and 7 months. Results of retinal vessels stained by cluster of differentiation 31 (CD31) showed that the number of retinal vessels was increased in GK rats at both 6 and 7 months. Retinal histological observation also evidenced such increase. Retinal mRNA expressions of hypoxia inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF), VEGFB and its receptors (VEGFR1/2), basic fibroblast growth factor (bFGF), and platelet-derived growth factor (PDGF) A/B were increased in GK rats at both 6 and 7 months. Retinal mRNA expressions of matrix metalloproteinase (MMP) 2/9 and insulin-like growth factor 1 (IGF-1) were increased at 7 months. Retinal mRNA expression of pigment epithelium-derived factor (PEDF) was increased in GK rats at 6 months. Serum contents of VEGF, bFGF, PDGFA, MMP2/9, IGF-1, PEDF were increased in GK rats at both 6 and 7 months, while PDGFB was increased at 7 months. In summary, our results indicate that retinal angiogenesis occurred in GK rats at 6 and 7 months, and the expressions of some angiogenesis related factors were increased during the development of DR in GK rats.

1. Abdel-Halim, S.M.,Guenii, A.,Luthman, H.,Grill, V.,Efendic, S.,Ostenson, C.G.(1994).Impact of diabetic inheritance on glucose tolerance and insulin-secretion in spontaneously diabetic GK Wistar rats.Diabetes,43,281-288.
2. Agardh, C.D.,Agardh, E.,Zhang, H.,Ostenson, C.G.(1997).Altered endothelial/pericyte ratio in Goto-Kakizaki rat retina.J. Diabetes Complicat.,11,58-162.
3. Ai-Latayfeh, M.,Silva, P.S.,Sun, J.K.,Aiello, L.P.(2012).Antiangiogenesis therapy for ischemic retinopathies.Cold Spring Harb. Perspect. Med.,2,a006411.
4. Albrecht, I.,Kopfstein, L.,Strittmatter, K.,Schomber, T.,Falkevall, A.,Hagberg, C.E.,Lorentz, P.,Jeltsch, M.,Alitalo, K.,Eriksson, U.,Christofori, G.,Pietras, K.(2010).Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis.PLoS One,5,e14109.
5. Aldebasi, Y.H.,Rahmani, A.H.,Khan, A.A.,Aly, S.M.(2013).The effect of vascular growth factor in the progression of bladder cancer and diabetic retinopathy.Int. J. Clin. Exp. Med.,6,239-251.
6. Beranek, M.,Kolar, P.,Tschoplova, S.,Kankova, K.,Vasku, A.(2008).Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy.Mol. Vis.,14,1114-1121.
7. Boosani, C.S.,Nalabothula, N.,Sheibani, N.,Sudhakar, A.(2010).Inhibitory effects of arresten on bFGF-induced proliferation, migration, and matrix metalloproteinase-2 activation in mouse retinal endothelial cells.Curr. Eye Res.,35,45-55.
8. Campochiaro, P.A.(2007).Molecular targets for retinal vascular diseases.J. Cell. Physiol.,210,575-581.
9. Cébe-Suarez, S.,Zehnder-Fjällman, A.,Ballmer-Hofer, K.(2006).The role of VEGF receptors in angiogenesis; complex partnerships.Cell. Mol. Life Sci.,63,601-615.
10. Chan, C.M.,Huang, J.H.,Chiang, H.S.,Wu, W.B.,Lin, H.H.,Hong, J.Y.,Hung, C.F.(2010).Effects of (-)-epigallocatechin gallate on RPE cell migration and adhesion.Mol. Vis.,3,586-595.
11. Cheung, N.,Mitchell, P.,Wong, T.Y.(2010).Diabetic retinopathy.Lancet,376,124-136.
12. Choudhuri, S.,Chowdhury, I.H.,Das, S.,Dutta, D.,Saha, A.,Sarkar, R.,Mandal, L.K.,Mukherjee, S.,Bhattacharya, B.(2015).Role of NF-κB activation and VEGF gene polymorphisms in VEGF up regulation in non-proliferative and proliferative diabetic retinopathy.Mol. Cell. Biochem.,405,265-279.
13. Cilenšek, I.,Mankoč, S.,Petrovič, M.G.,Petrovič, D.(2012).GSTT1 null genotype is a risk factor for diabetic retinopathy in Caucasians with type 2 diabetes, whereas GSTM1 null genotype might confer protection against retinopathy.Dis. Markers,32,93-99.
14. Fong, D.S.,Aiello, L.,Gardner, T.W.,King, G.L.,Blankenship, G.,Cavallerano, J.D.,Ferris, F.L.,Klein, R.,American Diabetes Association(2003).Diabetic retinopathy.Diabetes Care,26,226-229.
15. Giebel, S.J.,Menicucci, G.,McGuire, P.G.,Das, A.(2005).Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier.Lab. Invest.,85,597-607.
16. Gong, C.Y.,Lu, B.,Hu, Q.W.,Ji, L.L.(2013).Streptozotocin induced diabetic retinopathy in rat and the expression of vascular endothelial growth factor and its receptor.Int. J. Ophthalmol.,6,573-577.
17. Goto, Y.,Kakizaki, M.,Masaki, N.(1976).Production of spontaneous diabetic rats by repetition of selective breeding.Tohoku J. Exp. Med.,119,85-90.
18. Gustavsson, C.,Agardh, E.,Bengtsson, B.,Agardh, C.D.(2008).TNF-α is an independent serum marker for proliferative retinopathy in type 1 diabetic patients.J. Diabetes Complicat.,22,309-316.
19. Haurigot, V.,Villacampa, P.,Ribera, A.,Bosch, A.,Ramos, D.,Ruberte, J.,Bosch, F.(2012).Long-term retinal PEDF overexpression prevents neovascularization in a murine adult model of retinopathy.PLoS One,7,e41511.
20. He, S.,Kumar, S.R.,Zhou, P.,Krasnoperov, V.,Ryan, S.J.,Gill, P.S.,Hinton, D.R.(2010).Soluble EphB4 inhibition of PDGF-induced RPE migration in vitro.Invest. Opthalmol. Vis. Sci.,51,543-552.
21. Hoeben, A.,Landuyt, B.,Highley, M.S.,Wildiers, H.,Van Oosterom, A.T.,De Bruijn, E.A.(2004).Vascular endothelial growth factor and angiogenesis.Pharmacol. Rev.,56,549-580.
22. Huang, C.X.(2006).Experimental study of Fufang XueshuanTong on intervention of retinopathy in diabetic rats.Guangzhou:Sun Yat-Sen University.
23. Jenkins, A.J.,Zhang, S.X.,Rowley, K.G.,Karschimkus, C.S.,Nelson, C.L.,Chuang, J.S.,O'Neal, D.N.,Januszewski, A.S.,Croft, K.D.,Mori, T.A.,Draqicevic, G.,Harper, C.A.,Best, J.D.,Lyons, T.J.,Ma, J.X.(2007).Increased serum pigment epithelium-derived factor is associated with microvascular complications, vascular stiffness and inflammation in Type 1 diabetes.Diabet. Med.,24,1345-1351.
24. Kimura, K.,Toyota, T.,Kakizaki, M.,Kudo, M.,Takebe, K.,Goto, Y.(1982).Impaired insulin secretion in the spontaneous diabetes rats.Tohoku J. Exp. Med.,137,453-459.
25. Loukovaara, S.,Koivunen, P.,Inglés, M.,Escobar, J.,Vento, M.,Andersson, S.(2014).Elevated protein carbonyl and HIF-1α levels in eyes with proliferative diabetic retinopathy.Acta Ophthalmol.,92,323-327.
26. Manetti, M.,Guiducci, S.,Romano, E.,Ceccarelli, C.,Bellando-Randone, S.,Conforti, M.L.,Ibba-Manneschi, L.,Matucci-Cerinic, M.(2011).Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis.Circ. Res.,109,e14-e26.
27. Miyamoto, K.,Ogura, Y.,Nishiwaki, H.,Matsuda, N.,Honda, Y.,Kato, S.,Ishida, H.,Seino, Y.(1996).Evaluation of retinal microcirculatory alterations in the Goto-Kakizaki rat. A spontaneous model of noninsulin-dependent diabetes.Invest. Ophthalmol. Vis. Sci.,37,898-905.
28. Ogata, N.,Matsuoka, M.,Matsuyama, K.,Shima, C.,Tajika, A.,Nishiyama, T.,Wada, M.,Jo, N.,Higuchi, A.,Minamino, K.,Matsunaga, H.,Takeda, T.,Matsumura, M.(2007).Plasma concentration of pigment epithelium-derived factor in patients with diabetic retinopathy.J. Clin. Endocrinol. Metab.,92,1176-1179.
29. Olofsson, B.,Pajusola, K.,Kaipainen, A.,von Euler, G.,Joukov, V.,Saksela, O.,Orpana, A.,Pettersson, R.F.,Alitao, K.,Eriksson, U.(1996).Vascular endothelial growth factor B, a novel growth factor for endothelial cells.Proc. Natl. Acad. Sci. USA,93,2576-2581.
30. Omri, S.,Behar-Cohen, F.,de Kozak, Y.,Sennlaub, F.,Verssimo, L.M.,Jonet, L.,Savoldelli, M.,Omri, B.,Crisanti, P.(2011).Microglia/macrophages migrate through retinal epithelium barrier by a transcellular route in diabetic retinopathy: role of PKCζ in the Goto Kakizaki rat model.Am. J. Pathol.,179,942-953.
31. Perrin, R.M.,Konopatskaya, O.,Qiu, Y.,Harper, S.,Bates, D.O.,Churchill, A.J.(2005).Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor.Diabetologia,48,2422-2427.
32. Petrovič, D.(2013).Candidate genes for proliferative diabetic retinopathy.Biomed. Res. Int.,2013,540416.
33. Petrovič, M.G.,Korošec, P.,Košnik, M.,Osredkar, J.,Hawlina, M.,Peterlin, B.,Petrovič, D.(2008).Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy.Mol. Vis.,14,1382-1387.
34. Praidou, A.,Papakonstantinou, E.,Androudi, S.,Georgiadis, N.,Karakiulakis, G.,Dimitrakos, S.(2011).Vitreous and serum levels of vascular endothelial growth factor and platelet-derived growth factor and their correlation in patients with non-proliferative diabetic retinopathy and clinically significant macula oedema.Acta Ophthalmol.,89,248-254.
35. Punglia, R.S.,Lu, M.,Hsu, J.,Kuroki, M.,Tolentino, M.J.,Keough, K.,Levy, N.S.,Goldberg, M.A.,D'Amato, R.J.,Adamis, A.P.(1997).Regulation of vascular endothelial growth factor expression by insulin-like growth factor I..Diabetes,46,1619-1626.
36. Simó, R.,Carrasco, E.,García-Ramírez, M.,Hernández, C.(2006).Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy.Curr. Diabetes Rev.,2,71-98.
37. Slomiany, M.G.,Rosenzweig, S.A.(2004).IGF-1-induced VEGF and IGFBP-3 secretion correlates with increased HIF-α expression and activity in retinal pigment epithelial cell line D407.Invest. Ophthalmol. Vis. Sci.,45,2838-2847.
38. Sone, H.,Kawakami, Y.,Okuda, Y.,Sekine, Y.,Honmura, S.,Matsuo, K.,Segawa, T.,Suzuki, H.,Yamashita, K.(1997).Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes.Diabetologia,40,726-730.
39. Wang, X.,Wang, G.,Wang, Y.(2009).Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy.Am. J. Ophthalmol.,148,883-889.
40. Wilkinson, C.P.,Ferris III, F.L.,Klein, R.E.,Lee, P.P.,Agardh, C.D.,Davis, M.,Dills, D.,Kampik, A.,Pararajaseqaram, R.,Verdaquer, J.T.,Global Diabetic Retinopathy Project Group(2003).Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales.Ophthalmology,110,1677-1682.
41. Willard, A.L.,Herman, I.M.(2012).Vascular complications and diabetes: current therapies and future challenges.J. Ophthalmol.,2012,209538.
42. Wright, W.S.,McElhatten, R.M.,Messina, J.E.,Harris, N.R.(2010).Hypoxia and the expression of HIF-1α and HIF-2α in the retina of streptozotocin-injected mice and rats.Exp. Eye Res.,90,405-412.
43. Yamagishi, S.,Matsui, T.,Nakamura, K.,Ueda, S.,Noda, Y.,Imaizumi, T.(2008).Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications.Curr. Drug Targets,9,1025-1029.
44. Yang, R.,Liu, H.,Williams, I.,Chaqour, B.(2007).Matrix metalloproteinase-2 expression and apoptogenic activity in retinal pericytes: implications in diabetic retinopathy.Ann. NY Acad. Sci.,1103,196-201.
45. Zhu, X.F.,Zou, H.D.(2012).PEDF in diabetic retinopathy: a protective effect of oxidative stress.J. Biomed. Biotechnol.,2012,580687.
46. Ziello, J.E.,Jovin, I.S.,Huang, Y.(2007).Hypoxia-inducible factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia.Yale J. Biol. Med.,80,51-60.